Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 14/20 | 0.81 |
| ▸ | TUBB4A | P04350 | 13/20 | 0.81 |
| ▸ | TUBB | P07437 | 13/20 | 0.81 |
| ▸ | TUBA3C | P0DPH7 | 13/20 | 0.81 |
| ▸ | TUBA1B | P68363 | 13/20 | 0.81 |
| ▸ | TUBA4A | P68366 | 13/20 | 0.81 |
| ▸ | TUBB4B | P68371 | 13/20 | 0.81 |
| ▸ | TUBB3 | Q13509 | 13/20 | 0.81 |
| ▸ | TUBB2A | Q13885 | 13/20 | 0.81 |
| ▸ | TUBB8 | Q3ZCM7 | 13/20 | 0.81 |
| ▸ | TUBA3E | Q6PEY2 | 13/20 | 0.81 |
| ▸ | TUBA1A | Q71U36 | 13/20 | 0.81 |
| ▸ | TUBA1C | Q9BQE3 | 13/20 | 0.81 |
| ▸ | TUBB6 | Q9BUF5 | 13/20 | 0.81 |
| ▸ | TUBB2B | Q9BVA1 | 13/20 | 0.81 |
| ▸ | KRAS | P01116 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.60 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394054 | 0.90 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3834841 | 0.90 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1394056 | 0.90 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14175313 | 0.88 | TUBB1 (0.67) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Sulfamate SCHEMBL21980870 | 0.86 | TUBB1 (0.79) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Sulfamate SCHEMBL21980873 | 0.86 | TUBB1 (0.79) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Sulfamate SCHEMBL21980862 | 0.86 | TUBB1 (0.79) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Phosphoric Acid SCHEMBL5071914 | 0.86 | TUBB1 (0.71) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17232847 | 0.86 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17963706 | 0.86 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45907-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-RE45720-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-7384925-B2 | 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) | OXIGENE, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1438281-A4 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | OXIGENE INC (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060035868-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-6919324-B2 | For therapy of solid tumor cancers and other diseases associated with unwanted neovascularization | OXIGENE, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1438281-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | Oxigene, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035008-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | OXIGENE, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | TUBB1 9/4885TUBB4A 6/4885TUBB 17/4885 |
| US-20060035868-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | TUBB1 9/4885TUBB4A 6/4885TUBB 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.